Safety, immunogenicity and reactogenicity of the BNT162b2 and mRNA-1273 COVID-19 vaccines given as two-dose enhancers after two doses of ChAdOx1 nCoV-19 or BNT162b2 and the third dose after BNT162b2 (COV-BOOSTlin, a multifaze):

IgG concentration against SARS-CoV-2 protein, ELU / ml 28 days after the third dose 23,325 (20,030–27,162); 66 25,317 (20,996-30,528); 66 20,502 (16,473-25,517); 35 21,980 (16,476-29,324); 33 26,982 (22,056-33,008); 31 29,161 (23,093-36,823); 33 0 days of the fourth dose 3049 (2550–3646); 66 3469 (2730–4407); 66 2532 (1974–3247); 35 2571 (1874–3527); 34 3761 (2959–4780); 31 4769 (3421–6648); 32 14 days after the fourth dose 37,460 (31,996-43,857); 65 54,936 (46,826-64,452); 67 33,316 (26,942-41,198); 35 52,080 (41,163-65,894); 34 42,949 (34,148-54,019); 30 58,043 (46,693-72,150); 33 Change of route (14 days after the fourth dose). vs. 28 days after the third dose) 1 · 59 (1 · 41–1 · 78); 65 2 · 19 (1 · 90–2 · 52); 66 1 · 62 (1 · 35–1 · 95); 35 2 · 41 (1 · 90–3 · 05); 33 1 · 54 (1 · 35–1 · 76); 30 1 · 99 (1 · 71–2 · 31); 33 Change of route (14 days after the fourth dose). vs. 0 days of the fourth dose) 12 · 19 (10 · 37–14 · 32); 65 15 · 90 (12 · 92–19 · 58); 66 13 · 16 (10 · 24–16 · 91); 35 20 · 26 (15 · 09–27 · 21); 34 11 · 14 (9 · 21–13 · 47); 30 12 · 30 (9 · 39–16 · 11); 32 Cellular response (wild type), clear-forming cells 10⁶ PBMCs

28 days after the third dose 96 · 03 (65 · 68–140 · 42; 35 111 · 19 (75 · 87–162 · 95); 33 133 · 33 (81 · 31–218 · 62); 19 113 · 40 (57 · 93–221 · 98); 17 65 · 04 (37 · 76–112 · 03); 16 108 · 90 (75 · 81–156 · 43); 16 0 days of the fourth dose 19 · 32 (10 · 99–33 · 97); 36 35 · 32 (20 · 66–60 · 40); 34 18 · 85 (8 · 31–42 · 77); 20 42 · 13 (18 · 58–95 · 51); 16 19 · 93 (9 · 14–43 · 48); 16 30 · 20 (14 · 71–62 · 02); 18 14 days after the fourth dose 112 · 64 (80 · 61–157 · 38); 20 236 · 95 (146 · 04–384 · 48); 20 141 · 99 (92 · 57–217 · 80); 11 232 · 98 (116 · 70–465 · 12); 11 84 · 87 (51 · 94–138 · 66); 9 241 · 91 (118 · 79–492 · 64); 9 Change of route (14 days after the fourth dose). vs. 28 days after the third dose) 1 · 10 (0 · 72–1 · 70); 18 1 · 69 (1 · 22–2 · 34); 19 1 · 09 (0 · 63–1 · 89); 10 1 · 16 (0 · 79–1 · 70); 11 1 · 12 (0 · 54–2 · 31); 8 2 · 83 (2 · 02–3 · 96); 8 Change of route (14 days after the fourth dose). vs. 0 days of the fourth dose) 7 · 32 (3 · 24–16 · 54); 19 6 · 22 (3 · 90–9 · 92); 20 11 · 07 (4 · 21–29 · 12); 11 6 · 34 (2 · 89–13 · 92); 11 4 · 14 (1 · 04–16 · 54); 8 6 · 08 (3 · 86–9 · 56); 9 Cellular response (beta), cells that make up exactly 10⁶ PBMCs

*

For logistical reasons, only 50% of the study sites collected cellular immunology samples (close to an outdoor laboratory) in a basic COV-BOOST study; After the fourth dose, samples of cellular immunology were collected in the immunology cohort.

28 days after the third dose 98 · 34 (72 · 11–134 · 10); 35 108 · 85 (76 · 90–154 · 07); 33 132 · 70 (87 · 79–200 · 59); 19 120 · 52 (65 · 57–221 · 54); 17 68 · 89 (45 · 39–104 · 57); 16 97 · 69 (70 · 62–135 · 12); 16 0 days of the fourth dose 18 · 53 (10 · 60–32 · 37); 36 28 · 35 (15 · 40–52 · 19); 34 16 · 71 (7 · 50–37 · 22); 20 37 · 69 (16 · 24–87 · 46); 16 21 · 07 (9 · 64–46 · 06); n = 16 22 · 01 (9 · 11–53 · 20); 18 14 days after the fourth dose 85 · 55 (54 · 11–135 · 28); 20 245 · 84 (158 · 84–380 · 50); 20 96 · 25 (55 · 85–165 · 86); 11 256 · 42 (142 · 42–461 · 65); 11 74 · 08 (33 · 34–164 · 60); 9 233 · 50 (117 · 10–465 · 64); 9 Change of route (14 days after the fourth dose). vs. 28 days after the third dose) 0 · 98 (0 · 64–1 · 50); 18 1 · 96 (1 · 36–2 · 82); 19 0 · 93 (0 · 54–1 · 61); 10 1 · 30 (0 · 91–1 · 87); 11 1 · 03 (0 · 50–2 · 12); 8 3 · 45 (2 · 10–5 · 69); 8 Change of route (14 days after the fourth dose). vs. 0 days of the fourth dose) 5 · 47 (2 · 30–13 · 02); 19 8 · 48 (4 · 72–15 · 22); 20 7 · 63 (2 · 51–23 · 17); 11 8 · 98 (4 · 19–19 · 23); 11 3 · 46 (0 · 85–14 · 08); 8 7 · 91 (3 · 04–20 · 56); 9 Cellular response (delta), cells that make up exactly 10⁶ PBMCs

*

For logistical reasons, only 50% of the study sites collected cellular immunology samples (close to an outdoor laboratory) in a basic COV-BOOST study; After the fourth dose, samples of cellular immunology were collected in the immunology cohort.

28 days after the third dose 92 · 48 (66 · 90–127 · 85); 35 104 · 34 (72 · 95–149 · 24); 33 130 · 31 (92 · 00–184 · 58); 19 114 · 49 (61 · 51–213 · 11); 17 61 · 55 (36 · 64–103 · 38); 16 94 · 54 (66 · 74–133 · 91); 16 0 days of the fourth dose 16 · 40 (9 · 38–28 · 68); 36 35 · 93 (20 · 29–63 · 62); 34 18 · 39 (8 · 68–38 · 95); 20 41 · 93 (17 · 99–97 · 78); 16 14 · 22 (6 · 02–33 · 58); 16 31 · 31 (14 · 19–69 · 08); 18 14 days after the fourth dose 94 · 20 (66 · 92–132 · 60); 20 239 · 62 (155 · 19–369 · 97); 20 108 · 24 (69 · 20–169 · 28); 11 244 · 67 (141 · 79–422 · 20); 11 79 · 49 (46 · 55–135 · 72); 9 233 · 59 (111 · 99–487 · 24); 9 Change of route (14 days after the fourth dose). vs. 28 days after the third dose) 1 · 00 (0 · 68–1 · 49); 18 2 · 03 (1 · 39–2 · 97); 19 0 · 88 (0 · 56–1 · 38); 10 1 · 28 (0 · 89–1 · 84); 11 1 · 19 (0 · 59–2 · 40); 8 3 · 85 (2 · 39–6 · 21); 8 Change of route (14 days after the fourth dose). vs. 0 days of the fourth dose) 7 · 57 (3 · 32–17 · 25); 19 6 · 35 (3 · 51–11 · 49); 20 9 · 37 (3 · 56–24 · 67); 11 6 · 62 (2 · 87–15 · 25); 11 5 · 64 (1 · 27–25 · 06); 8 6 · 04 (2 · 48–14 · 68); 9